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ABSTRACT
Transrectal ultrasound-guided prostate biopsies (TRUSBx) are  common and increasingly
performed procedure. As this procedure can be complicated by infections, antibiotic prophylaxis
is widely used around the world to minimize these complications, but there is no consensus on the
most appropriate prophylaxis regimen. A total number of 412 patients who were referred fo
TRUSBx, was devided randomely into two groups. Group 1 received routine antibiotic prophylaxis
and Group 2 did not received Amikacin. Other premedications in both groups include ciprofloxacin,
metronidazole, ceftazidime and povodine iodine gel. 2 days after biopsy, all patients were investigated
about significant fever(e”38ºC). febrile patients were referred to urology clinic for further evaluation
about acute prostatitis or septicemia. There was 210 patients in group A and 202 patients in group
B. No significant difference was detected in mean age, prostatic volume, serum PSA level, re-
biopsy rate and pathology report between two groups. Acute prostatitis was developed in 2
patients (0.9%) in group A and 1 patient (0.5%) in group B that was not statistically significant.(P>0.05)
Removing amikacin from ciprofloxacin-based antibiotic prophylaxis along with local povodine
iodine would not put our patients in increased risk for infectious complications after TRUSBx.
Key words: Transrectal Ultrasound, Prostate Needle Biopsy,
Antibiotic Prophylaxis, Amikacine, Povodine Iodine.
INTRODUCTION
Transrectal ultrasound-guided prostate
biopsy (TRUSBx) is currently the gold-standard
method for diagnosis prostate cancer1. Using this
test, early detection of prostate cancer have been
possible and this has a role in decreasing death
rates from prostate cancer in recent years2,3.
The most common indication for TRUSBx
is elevated serum prostatic specific antigen (PSA)
level4. Since using PSA as a marker in early
detection of prostate cancer, the number of TRUS-
guided biopsies have dramatically increases5,6.
Extended core biopsy technique provided taking
at least 10 core biopsies transrectally, so Infectious
complications could occure after TRUSBx, including
fever, UTI, acute prostatitis, epididymo-orchitis and
even life-threatening septicemia8,7. Antibiotic
prophylaxis before TRUSBx had been shown to
reduce the infection rate significantly. For this
reasons, antibiotic prophylaxis is now  routinely
prescribed9,1.
Although there is no consensus about the
drug of choice and duration of antibiotic prophylaxis,
flouroquinolons especially ciprofloxacin are widely
used berore TRUSBx because of their good
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penetration into prostatic parenchyma, wide
coverage on colonic flora and coliforms, ease of
use and abscense of major complications. other
drugs such as aminoglycosides, metronidazole and
coamoxiclave had been used as alternative or in
addition to flouroquinolons2,3,10. The incidence of
infectious complications have been minimized by
these protocols, However they could not completely
eliminate infection11,12.
Use of povodine iodine as local gel or
suppository with other medications in some
researches was successful to induce significant
decrease of infection rate4,13. In our experience, as
well, just after adding Povodine iodine to our
multiple-drug regimen the infection rate after
TRUSBx reached near zero. We concluded that
Povodine iodine is the most effective part of regimen,
along with its ease to use and lower price. On the
other hand there is a possibility that using multiple
IV and oral antibiotics could raise antibiotic
prophylaxis beside their adverse effects (especially
nephrotoxicity for Amikacin) and more expensive
price. So this study was scheduled to adjust
antibiotic prophylaxis regimen, maintaining the
same low infection rate.
Patients and Methods
This was a double blind randomized
clinical trial study that was performed on 412
patients in our hospital from April 2012 to February
2013 who had referred for prostate biopsy due to
an elevated PSA or abnormal digital rectal findings.
At first we enrolled all patients with a prostate biopsy
in this time period (513) but a total of 119 patients
didn’t come back for follow up, so were excluded
from the study.
All patients received ciprofloxacine 500
mg two times per day and metronidazole 250 mg
three times per day per oral from 3 days before and
500 mg intravenous ceftazidime at the morning of
the biopsy. Patients then randomly were divided
into two groups, one group received additional 500
mg intravenous amikacin as routine prophylaxis
regimen in our hospital (group A) and the other
group did not received it.(group B) We  allocated
the first day for routine regimen and the day after
for new regimen and this was repeated respectively,
so all patients in a certain day, was received the
same prophylaxis regimen. For all patients 20 mg
lidocaine 2% and 30 mg povodine iodine 10% as
local gel injected into the rectum by a 5o ml gavage
syringe and 5 minutes later, TRUSBx were done for
them. Patients and the radiologist responsible for
biopsy were blind about the type of prophlaxis
regimen.
According to our biopsy protocol, each
prostate systematic biopsy included 10 core needle
biopsies or 12 if prostate volume was more than 50
ml. If a suspicious hypoechoic mass was found during
TRUS, then 1 to 2 targeted biopsies would be added.
All biopsies were done by a 18 guage needle and
automatic gun using a biopsy attachment on a
transrectal 5-9 MHz probe. Patients were followed-
up for 2 days later for possible signs of infection
including fever (oral temperature e”38ºC), chills,
dysuria and frequent urination. Patients with
temperature e”38ºC with or without other symptoms
were referred to urology department to investigate
about acute prostatitis. Diagnosis of acute prostatitis
was made by significant fever after transrectal
prostate biopsy and correlated rectal exam (large,
warm and  tender prostate) with or without WBC in
U/A or positive U/C.  Diagnosis of septicemia was
made by positive blood culture.
All patients were provided with informed
consent before the biopsy and all personal
informations reserved private. According to multiple
studies Povodine Iodine would decrease infection
rate sufficiently and Amikacine is not an essential
part of prophylaxis regimen for prostate biopsy
worldwide. So we did not put our patients in an
additional risk for infectious complications, However
the study protocol was approved by the Ethics
Committee. Data analysis performed by SPSS 16.0
(SPSS Inc., Chicago, Illinois, USA) using paired
sample t-test and chi2 test.
RESULTS
A total of 412 patients (210 in group A and
202 in group B) were included. Mean age of patients
in group A and B was 66.4  ± 9 and 65.9 ± 9
respectively. There was no significant difference in
mean age as well as mean prostate volume and
mean serum PSA level between two
groups.(P>0.05) (table1).
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Re-biopsy had been done in 6 patients of
group A and 4 patients in group B and in other
patients this was the first prostate biopsy. The mean
number of cores obtained in two group was nearly
similar. Additionally pathology reports showed that
36% of patient in group A and 35% in group B was
diagnosed as adenocarcinoma. These differences
were not significant as well.(table1)
Fever more than 38ºC was detected in 2
patients in group A (0.9%) and in 1 patient in group
B (0.5%) That was not significant.(p=0.58) (figure
1) Both 3 patients were referred to urology clinic
and all of them were admitted in hospital. Mean
age of affected patients was 62.6 years and one of
them in routine prophylaxis group had been
undergone re-biopsy. Blood and urine cultures were
negative and rectal examination, fever and urine
analysis in these patients was compatible with
diagnosis of “Acute prostatitis”. Medical treatment
was done with intravenous ciprofloxacin
successfully and after mean hospitalization time of
5 days, all three patients left hospital with good
general condition.
Table 1: Demographic data of patients
Group A Group B P-value
Mean age 66.4 ± 9 65.9 ± 9 0.3
Mean prostatic volume 58 ± 31 56 ± 26.6 0.39
Mean PSA(ng/ml)      17.7 ± 33.6     17.14 ± 40.6 0.92
Mean biopsy cores 12 ± 2 12.2 ± 2 0.22
Re-biopsy 2% 3% 0.52










Routine antibiotic regimen Regimen without Amikacin
Fig. 1: Frequency of acute prostatitis in two groups
DISCUSSION
Early prostate cancer detection programs
with serum PSA have surprisingely increased the
number of prostate biopsies2. TRUS-guided
biopsy(TRUSBx) is generally a less invasive and
safe method with some mainly minor complications.
Infection is the most sever one that can caused
hospitalization due to acute bacterial prostatits or
septicemia. But fortunately the most common
infectious complication is low grade fever due to
transient bacteremia. The rate of infectious
complications reported in different series ranges
from 0.8% to 17% 17,16 ,15.
Antibiotic prophylaxis before transrectal
prostate biopsy is now a routine premedication and
many researches revealed that it has significantly
decreased the infection rate after prostate
biopsy.(14,15) Although TRUSBx is a widely-used
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method, there is not a definite guideline about the
type of antibiotic regimen and its duration.
Fluoroquinilons are the most important part of
prophylaxis and ciprofloxacin is the most used
antibiotic as it quickly diffused in prostatic tissue to
achieve concentrations several fold greater than
the minimum inhibitory concentration for most
coliforms.(14) Nevertheless the duration of
ciprofloxacine usage is controversial and recent
series has been shown that the therapeutic effect
of a single dose ciprofloxacine is equivalent to 3 or
5-day regimen.(3,17,18)
Comparing the rate of infectious
complications with other studies is rather difficult,
as their different definition of infection and variety
of antibiotics used for prophylaxis. In the study of
AbuGhosh et al. rectal cleansing with povodine
iodine in addition to ciprofloxacin caused 42%
decrease in the risk of infectious complications
including fever, urinary tract infection or sepsis
comparing with ciprofloxacin alone, but it was not
statistically significant.(19) However significant
reduction has been published by park et al.(4) and
Ghafoori et al. using povodine iodine suppository
and gel respectively. In the study of park et al., a
single intravenous injection of a 3rd generation
cephalosporin just before biopsy and oral
administration of cefixime (100 mg two times per
day) begining at morning of the day of biopsy and
for more 5 days. infectious complications was
defined as fever, sepsis, acute prostatitis and UTI
that developed in o.3% of patients with antibiotic
prophylaxis and povodine iodine suppository. This
result is quite similar to our study, noting this fact
that our prophylaxis regimen was mainly different
except of 3rd generation cephalosporin and use of
povodine iodine.(4)
Madden et al. compare five different
antibiotic regimen three of them contained
ciprofloxacin and the other two did not. They
demonstrated that eliminating ciprofloxacin from
prophylaxis, would lead to significant increase in
infection rate, as with 3 or 5-day ciprofloxacin alone,
only 0.9% of patients were admitted for sever
infective complications and just one patient out of
454 by sepsis, but in patients who received co-
amoxiclave and gentamycin the rate of hospital
admission was 4.7% and 7 patient developed
sepsis.(14) on the other hand, adding amikacin to
ciprofloxacin-based regimen significantly reduced
the rate of infection (bacteremia and UTI) from 3.9%
to 1.4%, but this was significant just for UTI. Authors
concluded that adding amikacin to fluoroquinolone-
based antimicrobial prophylaxis significantly
reduces infection rate after prostate biopsy,
particularly in populations where ciprofloxacin
resistance is common. However, further studies
would be done to confirm these findings12.
In our experience, ciprofloxacine was the
main antibiotic that was administered for several
years as prophylaxis, but two years ago our
investigation revealed the rate of infectious
complications was as high as 20% with two reports
of septicemia so Hospital-acquired infection control
committee decided to change the prophylaxis
regimen as described above. Povodine iodine was
included in our prophylaxis protocol since 1 year
ago and due to our practice, as well as other
studies,(13,4) rate of acute prostatitis reached to zero.
This result along with nephrotoxicity of
aminoglycosides especially in older patients (like
patients referred for prostate biopsy) persuade us
to investigate whether it is necessary to continue
using amikacin. The result of this study proposed
that removing amikacin from a prophylaxis regimen
containing ciprofloxacin, ceftazidim and
metronidazol in addition to povodine iodine would
not increase the infection rate after prostate biopsy.
The rate of acute prostatitis and hospitalization in
our study was at the lowermost of range of the other
studies. This could be justified by multiple antibiotics
exists in our protocol and  the low ratio of re-biopsy
in our patients. More investigations is still needed
to achieve the same low rate of infection but with
the least systemic antibiotics.
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